hydroxychloroquine 600mg - for COVID-19 method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

clinical improvement 1.36 [0.87, 2.11]> 10%1 study (1 / -)91.0 %some concernnot evaluable moderatecrucial-
clinical improvement (14-day) 1.36 [0.87, 2.11]> 10%1 study (1 / -)91.0 %some concernnot evaluable moderatecrucial-
deaths 1.01 [0.06, 16.28]< 10%1 study (1 / -)49.7 %some concernnot evaluable moderatecrucial-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 1 pathologies: 87,95,94,90,91,97 97